Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Erweiterungsstudie, um mehr über die langfristige Sicherheit von Fazirsiran zu erfahren und herauszufinden, ob Fazirsiran Menschen mit Alpha-1-Antitrypsin-Lebererkrankungen helfen kann

6. November 2026 aktualisiert von: Takeda

Eine offene Phase-3-Verlängerungsstudie zur Bewertung der langfristigen Sicherheit und Wirksamkeit von Fazirsiran bei Teilnehmern mit Alpha-1-Antitrypsin-Mangel-assoziierter Lebererkrankung

The liver produces a protein called alpha-1 antitrypsin (AAT) which is released into the bloodstream. In some people, the liver makes an abnormal version of AAT, called Z-AAT. Z-AAT builds up in liver cells, and over time may lead to liver scarring (fibrosis), severe liver scarring (cirrhosis), and eventually end-stage liver disease. Fazirsiran is a medicine that reduces the production of the abnormal Z-AAT protein and its build-up in the liver.

The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-AAT protein. People who have taken part in previous fazirsiran studies (AROAAT2001 [NCT03945292], AROAAT2002 [NCT03946449] , TAK-999-3001 [NCT05677971], or TAK-999-3002 [NCT06165341]) can continue to receive fazirsiran in this study. Participants will receive fazirsian every 3 months, along with health checks, as long as they participate in this study, the study is ongoing or until health authorities in their country approve fazirsiran to be publicly available. The study may also provide information on whether fazirsiran has a long-term effect in reducing liver fibrosis or slowing down the progression of liver fibrosis in people with liver disease due to the abnormal Z-AAT protein.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

200

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • North Rhine-Westphalia
      • Aachen, North Rhine-Westphalia, Deutschland, 52074
        • Universitätsklinikum der RWTH Aachen
      • Funchal, Portugal, 9000-168
        • Hospital Nélio Mendonça
    • California
      • La Jolla, California, Vereinigte Staaten, 92037-1337
        • UCSD Altman Clinical and Translational Research Institute
      • Redwood City, California, Vereinigte Staaten, 94063
        • Stanford Medicine Outpatient Center
    • Florida
      • Gainesville, Florida, Vereinigte Staaten, 32610-3010
        • UF Clinical and Translational Science Institute
    • Iowa
      • Iowa City, Iowa, Vereinigte Staaten, 52242-1009
        • University Of Iowa Hospitals And Clinics
    • South Carolina
      • Charleston, South Carolina, Vereinigte Staaten, 29425-8900
        • Medical University of South Carolina - Hollings Cancer Center - PPDS
      • Cambridge, Vereinigtes Königreich, CB2 0QQ
        • Addenbrooke's Hospital
      • Edinburgh, Vereinigtes Königreich, EH16 4SA
        • Royal Infirmary of Edinburgh - PPDS
      • Vienna, Österreich, A-1090
        • Medizinische Universitat Wien (Medical University of Vienna)

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Participants must meet all of the following criteria to be eligible for inclusion in the study:
  • The participant is willing and able to understand and fully comply with study procedures and requirements, in the opinion of the investigator.
  • The participant is able to read, understand, and complete the study questionnaires electronically per investigator's judgment.
  • The participant has provided informed consent (ICF) (that is, in writing, documented via a signed and dated ICF) and any required privacy authorization before the initiation of any study procedures.

Note: For participants who comprehend, can provide informed consent, and are unable to sign the ICF, an impartial witness may sign the ICF on behalf of the participant after the participant has orally consented to the participant's participation in the study.

  • The participant enrolling in this open-label extension (OLE) study will have participated in a previously qualifying study, and will be considered for eligibility based on the following study-specific criteria:

  • AROAAT2001:

    • Participants with fibrosis may roll over into this OLE study after they reach their next regularly scheduled, Q12W visit.
    • Participants with fibrosis who have completed the AROAAT2001 study may be enrolled into the OLE study.
  • AROAAT2002:

    • Participants in Cohorts 1 and 1b may roll over after completing the 24-week primary study period.
    • Participants in Cohort 2 may roll over after completing the 48-week primary study period.
    • Participants who have completed the study may be enrolled into the OLE study.
  • TAK-999-3001 and TAK-999-3002:

    • Participants who have completed the treatment period in Study TAK-999-3001 or TAK-999-3002.
  • The participant is a nonsmoker (defined as: does not smoke cigarettes daily for at least 24 weeks) with current nonsmoking status confirmed by urine cotinine at Day 1.

    • E-cigarettes (vapor) are not permitted.
    • The participant may be on nicotine replacement (patch or gum). A positive urine cotinine result due to nicotine replacement is acceptable for enrollment at the discretion of the investigator.
  • The participant must have suitable venous access for blood sampling.

  • It must be confirmed that the participant does not have hepatocellular carcinoma (HCC). Participants will be screened for HCC with alpha-fetoprotein (AFP) and abdominal ultrasound. If the participant has any of the following, they will be required to have contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) imaging to exclude HCC before enrollment.

    • AFP >20 nanogram per milliliter (ng/mL).
    • AFP 15 to 19 ng/mL at enrollment if that is >2 times prestudy levels (if available).
    • Any liver lesion >10 millimeter (mm) (longest diameter) detected by ultrasound.
    • Poor visibility of liver on ultrasound.
  • A person of childbearing potential (POCBP) must have a negative urine pregnancy test performed within 3 days prior to Day 1 dosing in this study (sensitive to 25 International Unit [IU] human chorionic gonadotropin [hCG]).

  • The participant must use appropriate contraception methods (that is, highly effective methods for female and medically appropriate methods for male study participants) for the entire duration of the study. Participants who terminate early must use appropriate contraception methods for 6 months after the last dose of study intervention. Male participants who terminate early must not donate sperm for at least 6 months after the last dose of study intervention.

  • Sexual abstinence, for the purposes of this study, is only considered a highly effective method of contraception when considered to align with the preferred and usual lifestyle of the participant. It will be employed for the entire duration of the study and the 6 months after last dose of study intervention.

  • Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea methods are not considered "true" abstinence and are not acceptable methods of contraception.

Exclusion Criteria:

  • The participant will be excluded from the study if any of the following exclusion criteria are met:
  • The participant is likely to require major surgery. Major surgery typically requires at least 1 night in the hospital. Examples include laparoscopic surgery (except cholecystectomy and tubal ligation); Gastrointestinal tract (GI) tract surgery including 1 or more segments of the colon or terminal ileum; open resection of organs; large joint replacements; mastectomy with reconstruction; and spine, thoracic, vascular, or intracranial surgery.
  • The participant has evidence of other forms of chronic liver diseases, including viral hepatitis B or C, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease, alcoholic hepatitis, hemochromatosis, liver cancer, history of biliary diversion, or autoimmune hepatitis.
  • The participant has abnormal finding(s) of clinical relevance during the evaluation before the first study dosing that, in the opinion of the investigator, could adversely impact participant safety during the study or adversely impact study results. For US only: Participants with baseline emphysema may be allowed into the OLE if their lung disease has been stable.
  • The participant had significant protocol deviation(s) in Study AROAAT2001, AROAAT2002, TAK-999-3001, or TAK-999-3002 that would affect the conduct of this study.
  • The participant permanently discontinued investigational product because of an AE, adjudicated as related to the study intervention, in Study AROAAT2001, AROAAT2002, TAK-999-3001, or TAK-999-3002.
  • Female participants who became pregnant during Study AROAAT2001, AROAAT2002, TAK-999-3001, or TAK-999-3002, female participants who are lactating or planning to become pregnant during the study period; or males or female participants of childbearing potential not agreeing to continue using appropriate contraception methods through the conclusion of study participation.
  • The participant has a Child-Turcotte-Pugh (CTP) score >=7 OR (Model for End-Stage Liver Disease) MELD score >14.
  • The participant meets Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatinine criteria as per the protocol. All laboratory tests used as exclusion criteria may be repeated once and the repeat value may be used for study eligibility determination.
  • Participants who have a newly-diagnosed malignancy or recurrence of malignancy (except for resected cutaneous basal cell carcinoma, squamous cell carcinoma, superficial bladder tumors, or carcinoma in situ of the uterine cervix that has been treated with no evidence of recurrence).
  • The participant is experiencing a pulmonary exacerbation at the time of enrollment (participant enrollment may be temporarily delayed after the clinical resolution of an exacerbation).
  • The participant has unstable, poorly controlled, or severe hypertension. Participants may be reevaluated once their blood pressure is successfully controlled.
  • The participant has a history of more than moderate alcohol consumption within 12 months before the Day 1 visit.
  • The participant has a history of hypersensitivity or allergies to fazirsiran or any associated excipients.
  • The participant has any concomitant medical or psychiatric condition or social situation that would make it difficult to comply with protocol requirements or put the participant at additional safety risk.
  • The participant has a history of clinically significant hematologic, renal, hepatic, cardiovascular, infectious, pulmonary, neurologic, psychiatric, GI, systemic inflammatory, metabolic, or endocrine disorder or any other condition that, in the opinion of the investigator, rendered the participant a poor candidate for inclusion into the study.
  • The participant has a history of thromboembolic disease (including deep vein thrombosis or pulmonary embolism), within 24 weeks before enrollment; or is taking chronic anticoagulants. (Note: Participants taking stable doses of chronic anticoagulants may be allowed after consultation with the medical monitor, if they do not have cirrhosis or a history of liver decompensating events). Low-dose aspirin may be permitted on-study with the approval of the participant's local healthcare providers and discussion with study medical monitors.
  • The participant is unable to return for all scheduled study visits.
  • Enrollment of participants with symptomatic coronavirus disease 2019 (COVID-19) infection may be temporarily delayed at the discretion of the sponsor and investigator. Positive antibody testing for COVID-19 without other evidence of symptomatic current or recent active infection does not exclude participation.
  • The participant is a study site employee involved in the conduct of this study, an immediate family member (for example, spouse, parent, child, sibling), or is in a dependent relationship with a study site employee who is involved in conduct of this study, or may consent under duress.
  • The participant who, in the opinion of the investigator or the sponsor, will be uncooperative or unable to comply with study procedures.
  • The participant who participates in other studies involving an investigational product.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Fazirsiran 200 mg

Participants who are currently taking part in or who have completed their treatment in parent studies AROAAT2001 (NCT03945292), AROAAT2002 (NCT03946449), TAK-999-3001 [NCT05677971] and TAK-999-3002 (NCT06165341) will rollover in this study to receive fazirsiran, 200 milligrams (mg), injection, subcutaneously on Day 1 and once every 12 weeks (Q12W) thereafter until fazirsiran receives approval and is commercially available in the participant's country, until a participant withdraws from the study or the sponsor decides to terminate the study.

Fazirsiran will be injected subcutaneously.

Andere Namen:
  • TAK-999
  • ARO-AAT

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
Zeitfenster: From start of study drug administration (in current study) up to End of study (EOS) (current study [up to 10 years])

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not it is considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study intervention. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, suspected transmission of any infectious agent, an important medical event. AEs and SAEs including any pulmonary AEs or SAEs indicative of worsening pulmonary condition (example, pulmonary exacerbation, respiratory infection, significant pulmonary function test decline) will be reported.

From start of study drug administration (in current study) up to End of study (EOS) (current study [up to 10 years])
Number of Participants With Clinically Significant Changes From Baseline in Pulmonary Function Parameters
Zeitfenster: Baseline (current study), up to EOS (current study up to 10 years])

Standard pulmonary function parameters measured will be used to study lung function. Clinical significance of pulmonary function parameters will be determined at the investigator's discretion.

Baseline (current study), up to EOS (current study up to 10 years])
Number of Participants With Clinically Significant Changes in Vital Signs
Zeitfenster: From start of study drug administration (in current study) up to EOS (current study [up to 10 years])

Vital signs include body temperature, respiratory rate, sitting blood pressure (systolic and diastolic, resting more than 5 minutes), pulse, oxygen saturation. Clinical significance of vital signs will be determined at the investigator's discretion.

From start of study drug administration (in current study) up to EOS (current study [up to 10 years])
Number of Participants With Clinically Significant Changes in Laboratory Parameters
Zeitfenster: From start of study drug administration (in current study) up to EOS (current study [up to 10 years])

Laboratory parameters include hematology, biochemistry including liver tests, coagulation, and urinalysis. Clinical significance of laboratory parameters will be determined at the investigator's discretion.

From start of study drug administration (in current study) up to EOS (current study [up to 10 years])

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Participants With no Progression from Baseline of At least 1 Stage of Histologic Fibrosis on Liver Biopsy at Week 102
Zeitfenster: At Week 102 (current study)

Number of participants from Studies AROAAT2001 and AROAAT2002 with no progression from baseline of at least 1 stage of histologic fibrosis (by Meta-Analysis of Histological Data in Viral Hepatitis [METAVIR] staging) on liver biopsy at Week 102 will be reported.

At Week 102 (current study)
Number of Participants With Reduction from Baseline of At least 1 Stage of Histologic Fibrosis on Liver Biopsy at Week 102
Zeitfenster: At Week 102 (current study)

Number of participants from Studies AROAAT2001 and AROAAT2002 with baseline fibrosis of F1 or higher, a decrease from baseline of at least 1 stage of histologic fibrosis (by METAVIR staging) on liver biopsy at Week 102 will be reported.

At Week 102 (current study)
Change from Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by Periodic Acid Schiff Plus Diastase (PAS+D) Staining in Liver Biopsy at Week 102
Zeitfenster: Baseline (current study), Week 102 (current study)

Change from baseline in intrahepatic Z-AAT protein polymer burden assessed by PAS+D staining in liver biopsy for participants from Studies AROAAT2001 and AROAAT2002 will be assessed.

Baseline (current study), Week 102 (current study)
Change from Baseline in Intrahepatic Portal Inflammation Score at Week 102 in Liver Biopsy
Zeitfenster: Baseline (current study), Week 102 (current study)

Change in portal inflammation score in liver biopsy, based on pathology slide reads for participants from Studies AROAAT2001 and AROAAT2002 will be assessed. Inflammation will be assessed on a scale of 0-3, with higher scores showing more severe inflammation.

Baseline (current study), Week 102 (current study)
Change from Baseline in Liver Stiffness Assessed by Magnetic Resonance Elastography (MRE)
Zeitfenster: Baseline (current study), up to EOS (current study up to 10 years])

Change from baseline in MRE-derived liver stiffness will be assessed.

Baseline (current study), up to EOS (current study up to 10 years])
Change from Baseline in Liver Stiffness Assessed by Vibration-Controlled Transient Elastography (VCTE)
Zeitfenster: Baseline (current study), up to EOS (current study up to 10 years])

Change from baseline in VCTE-derived liver stiffness will be assessed.

Baseline (current study), up to EOS (current study up to 10 years])

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Study Director, Takeda

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

8. August 2023

Primärer Abschluss (Geschätzt)

2. Mai 2033

Studienabschluss (Geschätzt)

2. Mai 2033

Studienanmeldedaten

Zuerst eingereicht

2. Juni 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. Juni 2023

Zuerst gepostet (Tatsächlich)

12. Juni 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

6. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • TAK-999-3003
  • 2023-503497-21-00 (Ctis: EU CTIS)
  • 2023 (US NIH Stipendium/Vertrag)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD-Sharing-Zugriffskriterien

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF
  • CSR

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .